Long term outcomes demonstrate that piperacillin-tazobactam does not impact oncologic care, suggesting a need for targeted analysis.
While patients experiencing an SSI had poorer survival, piperacillin-tazobactam prophylaxis did not significantly affect oncologic care delivery. These results cement the long-term implications of perioperative complications in patients with cancer and highlight leveraging cancer registries for clinical trial data analysis.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: